Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Trial Identifier: QHD00011
Sponsor: Sanofi Pasteur, a Sanofi Company
Start Date: October 2019
Primary Completion Date: January 2020
Study Completion Date: June 2020
Condition: Healthy Volunteers; Influenza Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
BELGIUM Gent, BELGIUM, BE-9000
BELGIUM Wilrijk, BELGIUM, 2610
FRANCE Gieres, FRANCE, 38610
FRANCE Paris, FRANCE, 75014
FRANCE Pierre Benite Cedex, FRANCE, 69495
GERMANY Berlin, GERMANY, 10629
GERMANY Berlin, GERMANY, 13347
GERMANY Berlin, GERMANY, 10787
GERMANY Essen, GERMANY, 45136
GERMANY Oldenburg In Holstein, GERMANY, 23758
ITALY Genova, ITALY, IT-16132
ITALY Palermo, ITALY, 90127
NETHERLANDS Utrecht, NETHERLANDS, 3584 CX
POLAND Debica, POLAND, 39-200
POLAND Siemianowice Slaskie, POLAND, 41-103
POLAND Wola, POLAND, 43-225
POLAND Wroclaw, POLAND, 50-452